INSTITUTO DE BIOTECNOLOGIA Y BIOLOGIA MOLECULAR
Unidad Ejecutora - UE
congresos y reuniones científicas
New vaccine against pertussis.
BOTTERO DANIELA; GAILLARD MARÍA EMILIA; ERREA AGUSTINA; ORMAZABAL MAXIMILIANO; ZURITA EUGENIA; MORENO GRISELDA; BARTEL ERIKA; FLORES DARÍO; CASTUMA CELINA; RUMBO MARTÍN; DANIELA F. HOZBOR,
Congreso; 8th Vaccine & ISV Congress.; 2014
Pertussis is a current public health problem even in countries with high vaccination coverage. The alarming situation of pertussis has moved the scientific community and health professionals to seek for an understanding of the causes of this new situation, review and implement new strategies for the disease control. Several factors that could explain the disease resurgence have been proposed, most of them associated with vaccines currently in use. In this context, while optimization of the use of current vaccines is welcomed, there is an urgent need to develop new and improved vaccines. We have previously demonstrated that the outer membrane vesicles obtained from Bordetella pertussis are good vaccine candidates to protect against pertussis. Here we formulated OMVs derived from B. pertussis (OMVsBp) and from B. parapertussis (OMVsBpp) with diphtheria (d) and tetanus (T) toxoids (TdapOMVsBp+OMVsBpp) to evaluate its protective capacity against B. pertussis and B. parapertussis infection. To this aim we used the accepetd mice intranasal challenge model. Mice were immunized with TdapOMVsBp+OMVsBpp and challenged with sublethal doses of B. pertussis or B. parapertussis. Comparisons with a current commercial Tdap vaccine used was also performed. We observed that TdapOMVsBp+OMVsBpp protected against both Bordetella species, whereas current commercial Tdap vaccine showed good level of protection against B. pertussis but little protection against B. parapertussis. To determine the best combination of OMVsBp and OMVsBpp we performed a dose?response protection assays. We detected that the combination of the Tdap containing OMVsBpp in concentrations of 9μg per dose+OMVsBp in concentrations of 0,75μg per dose renders excellent levels of protection against both strains and also very low toxicity, comparable to comercial Tdap evaluated by IL6 serum levels post vaccination and weight gain test. All presented results showed that TdapOMVsBp+OMVsBpp is an interesting formulation to be considered for the development of novel acellular multi-antigen vaccine against B. pertussis but also B. parapertussis.